GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bavarian Nordic A/S (OCSE:BAVA) » Definitions » Cyclically Adjusted Price-to-FCF

Bavarian Nordic A/S (OCSE:BAVA) Cyclically Adjusted Price-to-FCF : (As of Jun. 09, 2024)


View and export this data going back to 1998. Start your Free Trial

What is Bavarian Nordic A/S Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Bavarian Nordic A/S Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Bavarian Nordic A/S's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bavarian Nordic A/S Cyclically Adjusted Price-to-FCF Chart

Bavarian Nordic A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Bavarian Nordic A/S Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Bavarian Nordic A/S's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Bavarian Nordic A/S's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bavarian Nordic A/S's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bavarian Nordic A/S's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Bavarian Nordic A/S's Cyclically Adjusted Price-to-FCF falls into.



Bavarian Nordic A/S Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Bavarian Nordic A/S's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Bavarian Nordic A/S's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=5.617/118.4000*118.4000
=5.617

Current CPI (Mar. 2024) = 118.4000.

Bavarian Nordic A/S Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -3.462 99.700 -4.111
201409 -1.938 99.700 -2.301
201412 13.776 99.400 16.409
201503 16.457 100.200 19.446
201506 -8.639 100.300 -10.198
201509 -1.291 100.200 -1.525
201512 -4.700 99.800 -5.576
201603 -2.448 100.200 -2.893
201606 -2.881 100.600 -3.391
201609 -6.366 100.200 -7.522
201612 15.262 100.300 18.016
201703 4.158 101.200 4.865
201706 7.430 101.200 8.693
201709 -2.173 101.800 -2.527
201712 -5.521 101.300 -6.453
201803 -5.829 101.700 -6.786
201806 -3.884 102.300 -4.495
201809 -0.721 102.400 -0.834
201812 -1.876 102.100 -2.175
201903 -4.469 102.900 -5.142
201906 -8.743 102.900 -10.060
201909 -4.559 102.900 -5.246
201912 -58.216 102.900 -66.985
202003 9.225 103.300 10.573
202006 3.505 103.200 4.021
202009 4.020 103.500 4.599
202012 -15.424 103.400 -17.662
202103 -3.619 104.300 -4.108
202106 -5.991 105.000 -6.756
202109 -0.798 105.800 -0.893
202112 -11.968 106.600 -13.293
202203 -3.992 109.900 -4.301
202206 -3.449 113.600 -3.595
202209 -0.875 116.400 -0.890
202212 -8.226 115.900 -8.403
202303 -6.200 117.300 -6.258
202306 1.652 116.400 1.680
202309 1.716 117.400 1.731
202312 4.414 116.700 4.478
202403 5.617 118.400 5.617

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Bavarian Nordic A/S  (OCSE:BAVA) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Bavarian Nordic A/S Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Bavarian Nordic A/S's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Bavarian Nordic A/S (OCSE:BAVA) Business Description

Industry
Traded in Other Exchanges
Address
Philip Heymans Alle 3, Hellerup, DNK, DK-2900
Bavarian Nordic A/S is a biotechnology company focused on the development, manufacturing, and commercialization of cancer immunotherapies and vaccines for infectious diseases. The company has a specific focus on diseases for which the unmet medical need is high. Bavarian generates revenue through government research and development and supply contracts, and from its commercial partnerships. The vast majority of the company's revenue is generated in the United States, Germany, and other geographic markets.

Bavarian Nordic A/S (OCSE:BAVA) Headlines

No Headlines